Kalveer Flora, MPharm, London North West University Healthcare National Health Service Trust, explains how rheumatology specialists have led the way in biosimilar adoption.
Transcript
In terms of my specialty, which is rheumatology, I think rheumatology pharmacists and rheumatologists have actually led the way in adopting biosimilars, only because we’ve had so much experience with biosimilars compared with dermatologists and gastroenterologists. So I think the rheumatologists have really led the way in providing that real-world evidence, that confidence, that transferrable data.
Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.